Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Buy
57
GKOS Quote, Financials, Valuation and Earnings
Last price:
$150.05
Seasonality move
:
9.96%
Day range:
$147.07 - $151.92
52-week range:
$74.75 - $151.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.02x
P/B ratio:
12.24x
Volume:
445.8K
Avg. volume:
541.8K
1-year change:
80.18%
Market cap:
$8.2B
Revenue:
$314.7M
EPS (TTM):
-$2.96
Analysts' Opinion
-
Consensus RatingGlaukos has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Glaukos has an estimated downside of -0.75% from its current price of $148.36.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $148.36.
Fair Value
-
According to the consensus of 0 analysts, Glaukos has -0.75% downside to fair value with a price target of -- per share.
GKOS vs. S&P 500
-
Over the past 5 trading days, Glaukos has overperformed the S&P 500 by 1.18% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Glaukos does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Glaukos has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Glaukos reported revenues of $96.7M.
Earnings Growth
-
Glaukos has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Glaukos reported earnings per share of -$0.39.
Enterprise value:
8B
EV / Invested capital:
11.00x
Price / LTM sales:
21.02x
EV / EBIT:
--
EV / Revenue:
22.13x
PEG ratio (5yr expected):
-4.99x
EV / Free cash flow:
-98.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$276.1M
Return On Assets:
-16.02%
Net Income Margin (TTM):
-41.51%
Return On Equity:
-27.46%
Return On Invested Capital:
-20.29%
Operating Margin:
-25.51%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $284.9M | $303.6M | $360.3M | $78M | $96.7M | |
| Gross Profit | $216.3M | $229.7M | $276.1M | $59.5M | $74.1M | |
| Operating Income | -$86.4M | -$120.8M | -$116.1M | -$28M | -$24.7M | |
| EBITDA | -$40.3M | -$77M | -$97M | -$15.3M | -$7.4M | |
| Diluted EPS | -$1.90 | -$2.69 | -$2.96 | -$0.63 | -$0.39 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $454.4M | $501.8M | $448.8M | $399.5M | $397.3M | |
| Total Assets | $994.5M | $1.1B | $1B | $948.6M | $926.5M | |
| Current Liabilities | $46.7M | $63.5M | $60.6M | $67.1M | $71.7M | |
| Total Liabilities | $333M | $463.1M | $459.9M | $471M | $258M | |
| Total Equity | $661.6M | $601M | $548.6M | $477.7M | $668.5M | |
| Total Debt | $186.7M | $279.7M | $281.1M | $282.4M | $56.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33.6M | -$51.2M | -$72.5M | -$8.2M | -$9.6M | |
| Cash From Investing | $19.3M | $43.7M | $23.1M | $14.9M | $30.6M | |
| Cash From Financing | $7.3M | $8.3M | $38.7M | $7.5M | $9.7M | |
| Free Cash Flow | -$65M | -$75.5M | -$81.3M | -$11.5M | -$11M | |
GKOS
Sector
Market Cap
$8.2B
$45.6M
Price % of 52-Week High
97.66%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
80.18%
-31.35%
Beta (5-Year)
1.034
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$144.73
200-day SMA
Buy
Level
$119.54
Bollinger Bands (100)
Buy
Level
124.41 - 140.29
Chaikin Money Flow
Buy
Level
54.9M
20-day SMA
Buy
Level
$141.76
Relative Strength Index (RSI14)
Buy
Level
58.96
ADX Line
Buy
Level
9.31
Williams %R
Neutral
Level
-20.5661
50-day SMA
Buy
Level
$138.13
MACD (12, 26)
Buy
Level
2.48
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
66.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.326)
Sell
CA Score
(Annual)
Level (-0.8476)
Buy
Beneish M-Score
(Annual)
Level (-2.8011)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (0.835)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Stock Forecast FAQ
In the current month, GKOS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GKOS average analyst price target in the past 3 months is --.
-
Where Will Glaukos Stock Be In 1 Year?
According to analysts, the consensus estimate is that Glaukos share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Glaukos?
Analysts are divided on their view about Glaukos share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Glaukos is a Sell and believe this share price will rise from its current level to --.
-
What Is Glaukos's Price Target?
The price target for Glaukos over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GKOS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Glaukos is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GKOS?
You can purchase shares of Glaukos via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Glaukos shares.
-
What Is The Glaukos Share Price Today?
Glaukos was last trading at $150.05 per share. This represents the most recent stock quote for Glaukos. Yesterday, Glaukos closed at $148.36 per share.
-
How To Buy Glaukos Stock Online?
In order to purchase Glaukos stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 6.38% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 0.85% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.46% over the past day.
